Nippon Chemiphar CoTSE:4539 +1.38%59 EBITDA Margin % is 5.49% as of Mar. 2026, which is 20% below its 10-year median of 6.88. GuruFocus rates TSE:4539 with a GF Score™ of 59/100 and a GF Value™ of 円1,705.64 (Fairly Valued). The stock has 9 warning signs investors should review. Among 961 Drug Manufacturers companies, Nippon Chemiphar Co ranks worse than 65.04% on this metric.
Nippon Chemiphar Co (TSE:4539) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nippon Chemiphar Co EBITDA Margin % Related Terms
Nippon Chemiphar Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Nippon Chemiphar Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nippon Chemiphar Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nippon Chemiphar Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nippon Chemiphar Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nippon Chemiphar Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nippon Chemiphar Co (TSE:4539) has a EBITDA Margin % of 5.49% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nippon Chemiphar Co and its competitors. This is 20% below median its historical median of 6.88. Over the past decade, Nippon Chemiphar Co's EBITDA Margin % has ranged from 4.58 to 11.48. According to the industry distribution chart, Nippon Chemiphar Co ranks #625 out of 961 companies in the Drug Manufacturers industry, placing it in the top 65%.
Is Nippon Chemiphar Co's EBITDA Margin % too high?
Nippon Chemiphar Co's current EBITDA Margin % of 5.49% is 20% below median its 10-year median of 6.88. Over the past 10 years, this metric has ranged from a low of 4.58 to a high of 11.48. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Nippon Chemiphar Co's value of 5.49% is 56% below this industry median. Based on the distribution chart, Nippon Chemiphar Co ranks #625 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Nippon Chemiphar Co has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nippon Chemiphar Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Nippon Chemiphar Co ranks #625 out of 961 companies for EBITDA Margin %. This places Nippon Chemiphar Co in the lower half of its industry. The industry median EBITDA Margin % is 12.49. Nippon Chemiphar Co's value of 5.49% is 56% below this benchmark. Historically, Nippon Chemiphar Co's own EBITDA Margin % has ranged from 4.58 to 11.48 over the past decade. While the company's 10-year median is 6.88 vs. the industry median of 12.49, Nippon Chemiphar Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nippon Chemiphar Co's current EBITDA Margin % of 5.49% is 56% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nippon Chemiphar Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nippon Chemiphar Co's current EBITDA Margin % is 5.49%, which is 20% below median its own 10-year median of 6.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nippon Chemiphar Co stock overvalued right now?
Based on GuruFocus' analysis, Nippon Chemiphar Co (TSE:4539) is currently considered Fairly Valued. The stock's GF Value™ is 円1,705.64, compared to a current price of 円1,692.00 — trading 0.8% below its estimated fair value. The current EBITDA Margin % is 5.49%, which is 20% below median its 10-year median of 6.88 and 56% below the Drug Manufacturers industry median of 12.49. Nippon Chemiphar Co's overall GF Score™ is 59/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nippon Chemiphar Co (TSE:4539), the current EBITDA Margin % is 5.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nippon Chemiphar Co (TSE:4539) Overvalued in 2026?
Based on GuruFocus' analysis, Nippon Chemiphar Co stock appears to be undervalued.
The current stock price of 円1,692.00 is trading 0.8% below its estimated GF Value™ of 円1,705.64.
GuruFocus considers Nippon Chemiphar Co to be Fairly Valued.
Key valuation signals for TSE:4539:
EBITDA Margin %: 5.49% (20% below median its 10-year median of 6.88)
GF Value™: 円1,705.64 vs. price of 円1,692.00 (0.8% below fair value)
Industry Position: 56% below the Drug Manufacturers median (#625 of 961)
No single metric tells the full story. See the TSE:4539 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nippon Chemiphar Co Ltd produces and sells medicines for medical use. The company also produces medical, health and cosmetics products. Nippon Chemiphar sterilizes medical instruments for hospitals and operates nursing home for elderly.
59GF Score
Get the complete analysis for TSE:4539
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4539 has been successfully added to your 
